Literature DB >> 9568688

The relationship between humoral and cellular immunity to IA-2 in IDDM.

T M Ellis1, D A Schatz, E W Ottendorfer, M S Lan, C Wasserfall, P J Salisbury, J X She, A L Notkins, N K Maclaren, M A Atkinson.   

Abstract

Autoantibodies to the neuroendocrine protein insulinoma-associated protein 2 (IA-2), a member of the tyrosine phosphatase family, have been observed in individuals with or at increased risk for IDDM. Because this disease is thought to result from a T-cell-mediated autoimmune destruction of the insulin-producing pancreatic beta-cells, we analyzed humoral and cellular immune reactivity to this autoantigen to further define its role in the pathogenesis of IDDM. Peripheral blood mononuclear cells (PBMC) from individuals with newly diagnosed IDDM or at varying levels of risk for the disease were stimulated in vitro with the entire 42-kDa internal domain of IA-2 (amino acids 603-979), a series of control antigens (glutathionine-S-transferase, tetanus toxoid, Candida albicans, mumps, bovine serum albumin), and a mitogen (phytohemagglutinin). The frequency and mean stimulation index of PBMC proliferation against IA-2 was significantly higher in newly diagnosed IDDM subjects (14 of 33 [42%]; 3.8+/-4.5 at 10 microg/ml) and autoantibody-positive relatives at increased risk for IDDM (6 of 9 [66%]; 3.9+/-3.2) compared with autoantibody-negative relatives (1 of 15 [7%]; 1.8+/-1.0) or healthy control subjects (1 of 12 [8%]; 1.5+/-1.0). The frequencies of cellular immune reactivities to all other antigens were remarkably similar between each subject group. Sera from 58% of the newly diagnosed IDDM patients tested were IA-2 autoantibody positive. Despite investigations suggesting an inverse association between humoral and cellular immune reactivities against islet-cell-associated autoantigens, no such relationship was observed (rs=0.18, P=0.39) with respect to IA-2. These studies support the autoantigenic nature of IA-2 in IDDM and suggest the inclusion of cellular immune responses as an adjunct marker for the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9568688     DOI: 10.2337/diabetes.47.4.566

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  10 in total

Review 1.  T-cell reactivity to beta-cell antigens in human insulin-dependent (type 1) diabetes mellitus. Implications for diagnosis and therapy.

Authors:  B O Roep
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  T-cell response to proinsulin and insulin in type 1 and pretype 1 diabetes.

Authors:  D Dubois-LaForgue; J C Carel; P F Bougnères; J G Guillet; C Boitard
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

Review 3.  The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure.

Authors:  Bart O Roep
Journal:  Diabetologia       Date:  2003-03-22       Impact factor: 10.122

4.  Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.

Authors:  David B Sacks; Mark Arnold; George L Bakris; David E Bruns; Andrea Rita Horvath; M Sue Kirkman; Ake Lernmark; Boyd E Metzger; David M Nathan
Journal:  Diabetes Care       Date:  2011-06       Impact factor: 19.112

5.  Combinations of common chronic paediatric diseases deviate the immune response in diverging directions.

Authors:  L Nilsson; A Kivling; M Jalmelid; K Fälth Magnusson; M Faresjö
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

Review 6.  T-cell epitopes in type 1 diabetes.

Authors:  Constadina Panagiotopoulos; Jacqueline D Trudeau; Rusung Tan
Journal:  Curr Diab Rep       Date:  2004-04       Impact factor: 4.810

Review 7.  Diabetes type 1: Can it be treated as an autoimmune disorder?

Authors:  Natalia G Vallianou; Theodora Stratigou; Eleni Geladari; Christopher M Tessier; Christos S Mantzoros; Maria Dalamaga
Journal:  Rev Endocr Metab Disord       Date:  2021-03-17       Impact factor: 6.514

8.  Immune response after autologous hematopoietic stem cell transplantation in type 1 diabetes mellitus.

Authors:  Lei Ye; Li Li; Bing Wan; Minglan Yang; Jie Hong; Weiqiong Gu; Weiqing Wang; Guang Ning
Journal:  Stem Cell Res Ther       Date:  2017-04-18       Impact factor: 6.832

9.  Role of immune system modulation in prevention of type 1 diabetes mellitus.

Authors:  Gamal Abdulrhman Hassan; Hamdy Ahmad Sliem; Abousree Taha Ellethy; Mahmoud El-Sawy Salama
Journal:  Indian J Endocrinol Metab       Date:  2012-11

Review 10.  On type 1 diabetes mellitus pathogenesis.

Authors:  Stavroula A Paschou; Nektaria Papadopoulou-Marketou; George P Chrousos; Christina Kanaka-Gantenbein
Journal:  Endocr Connect       Date:  2017-11-30       Impact factor: 3.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.